EMA recommends Shire's Gaucher drug; Neuralstem raises $10M;

@FierceBiotech: On its 10th birthday, the importance of sequencing is still debated. Article | Follow @FierceBiotech

 @JohnCFierce: Venter on sequencing: "I think it's far more important than walking on the Moon; not much has happened since walking on the Moon." | @JohnCFierce

> The EMA recommended approval of Shire's Gaucher's disease treatment Vpriv following an accelerated approval process. Report

> The first big pharma apps specially designed for Apple's iPad have started to emerge, with Pfizer and Sanofi leading the charge with upgrades to their existing iPhone apps. Report

> Neuralstem plans to raise $10 million in a registered direct offering. The company plans to proceeds for working capital and general corporate purposes. Neuralstem release

> ImmunoGen says partner Sanofi-Aventis has initiated a Phase I clinical trial with SAR650984, an investigational antibody that targets cancer cells expressing the CD38 protein antigen. The trial earns ImmunoGen a  $1 million milestone payment. Release

And Finally... BNet's Jim Edwards takes a look at me-too drugs being developed by several Big Pharma companies. Article

Suggested Articles

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.

Halozyme CEO Helen Torley discusses how the company stayed alive after its lead program, a treatment for pancreatic cancer, failed in phase 3.

The under-active genes that cause heart problems and poor muscle movement in Down syndrome may also impede the growth of solid tumors, a study found.